Shanghai, China, November 30, 2012: Hutchison MediPharma (HMP) announced that it is honored to have received the 2012 Alliance of the Year Award, presented by Elsevier Business Intelligence and the BayHelix Group, for its agreement to co-develop and commercialize Volitinib (HMPL-504) with AstraZeneca. This award recognizes a ground breaking biopharmaceutical collaboration agreement involving a Chinese entity.
Moreover, the companies’ Volitinib collaboration was also shortlisted for the 2012 SCRIP Award for Licensing Deal of the Year, one of the most prestigious awards in the biopharmaceutical field. Shortlisted candidates were carefully selected by a panel of industry judges based on innovation, dedication and impact within the pharmaceutical and biotech industries.
In 2011 HMP and AstraZeneca entered into a global licensing, co-development, and commercialization agreement for Volitinib, a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib was discovered and developed in China by HMP and is currently in Phase I clinical trials. It is a potential treatment for gastric cancer and non-small cell lung cancer, which are large unmet needs globally, particularly in China. The molecule has shown to inhibit the growth of tumors in a series of pre-clinical disease models, especially for tumors with c-Met signaling such as gene amplification or c-Met overexpression.
The 2012 BayHelix-Elsevier Awards were announced during an awards ceremony luncheon at the PharmAsia Summit in Shanghai. Award recipients were selected from a list of nominees submitted by members of the China and global pharmaceutical communities. “HMP and AstraZeneca were awarded for completing a global licensing, co-development, and commercialization agreement for Volitinib, a novel, targeted therapy entering Phase I clinical trial for the treatment of cancer. This partnership represents the first time a major pharmaceutical company has directly licensed a novel clinical ready stage molecule from a biotech company in China, with plans to develop and commercialize it globally, with record setting initial cash payment of US$20 million and further milestone payments of US$120 million.”
SCRIP Intelligence, the leading news, data and intelligence service for the global pharmaceutical industry, announced the shortlist for its internationally renowned annual awards ceremony, the SCRIP Awards 2012. The SCRIP Awards recognize the best companies by identifying those with growth in areas outside of traditional borders in the pharmaceutical and biotechnology industries.
About Elsevier Business Intelligence
Elsevier Business Intelligence is a global information leader in the healthcare sector providing regulatory, business and reimbursement insights that are vital to the industry. Through their publications, conferences, e-learning, databases, and reports regarding biopharmaceutical and medical device professionals, Elsevier Business Intelligence provides news and information with indispensable understanding and analysis. Its leading publications include PharmAsia News, IN VIVO and “The Pink Sheet.” For more information visit: www.elsevierbi.com.
About BayHelix Group
BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. It aspires to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: www.bayhelix.org.
About SCRIP Intelligence
SCRIP Intelligence is the leading source of news and strategic analysis for the global pharmaceutical industry. Using their vast network and connections, SCRIP filters and presents vital industry information with critical insight and analysis regarding drug discovery, development value chain, regulatory news, product approvals and rejections, and key corporate events. Being a large global presence, they are able provide a holistic perspective ranging from small biotech start-ups to multinational giants, research boutiques to generic manufacturers. For more information visit: www.scripintelligence.com.
AstraZeneca is a global, innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Operating in over 100 countries and employing over 57,200 people, AstraZeneca’s innovative medicines are used by millions of physicians and patients worldwide. For more information visit: www.astrazeneca.com.
HMP is a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China. For more information, visit www.hmplglobal.com